We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) set the ball rolling for pharma and medical device manufacturer fourth-quarter 2021 earnings on Jan 26, before the opening bell. The world's biggest healthcare products maker continued its long streak of earnings beat and outpaced revenue estimates. Further, the company offered upbeat full-year outlook.
Earnings per share came in at $1.86, beating the Zacks Consensus Estimate of $1.81 and declining 1.1% from the year-ago quarter. Revenues grew 8.3% year over year to $22.5 billion and edged past the Zacks Consensus Estimate of $21.6 billion. The stronger performance was driven by strong sales for blockbuster immunology and cancer drugs, as well as consumer-health products such as Tylenol and Listerine.
For 2021, Johnson & Johnson expects revenues in the range of $90.5-$91.7 billion, indicating year-over-year increase of 9.5%-11%, and earnings per share guidance of $9.40-$9.60, up 17.1-19.6% year over year. The Zacks Consensus Estimate is pegged at $88.7 billion for revenues and $8.89 for earnings per share.
Additionally, the company expects the phase 3 COVID-19 vaccine data, which will be released early next week, to be robust, matching expectations that it will rival the efficacy offered by the Moderna (MRNA - Free Report) and Pfizer (PFE - Free Report) vaccines. JNJ vaccine is a big deal as it requires just one dose and can be stored at room temperature unlike its rivals (read: Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?).
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high. Currently, the stock has a Zacks Rank #3 (Hold) and VGM Score of B.
ETFs in Focus
Given this, investors should closely watch the movement of the stock and ETFs having a largest allocation to this diversified drug maker. Below we have highlighted them (see: all the Healthcare ETFs here).
This ETF provides exposure to 43 companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. Of these, Johnson and Johnson takes the top spot, accounting for 23% share. The product has $366.8 million in AUM and charges 42 bps in fees and expenses. Volume is lower as it exchanges about 14,000 shares a day. The fund has a Zacks ETF Rank #3 (Hold) with a High risk outlook.
The most-popular healthcare ETF, XLV follows the Health Care Select Sector Index. This fund manages nearly $26.4 billion in its asset base and trades in heavy volume of around 7.6 million shares. Expense ratio comes in at 0.13%. In total, the fund holds 63 securities in its basket, with JNJ taking the top spot, accounting for 10.1% of the assets. Pharma accounts for 29.3% share from a sector look, while healthcare equipment and supplies, healthcare providers and services, and biotech have a double-digit exposure each. It has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook (read: 4 Sector ETFs & Stocks to Bet on Q4 Earnings).
iShares Evolved U.S. Innovative Healthcare ETF
This actively managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector. Holding 252 stocks in its basket, JNJ is the top firm with a 9.5% allocation. The product has accumulated $34.1 million in its asset base and trades in a meager volume of 12,000 shares per day on average. It charges 18 bps in annual fees.
This fund offers exposure to 123 securities by tracking the Dow Jones U.S. Health Care Index. Here again, Johnson & Johnson dominates the fund’s returns with 8.8% of the total assets. In terms of industrial exposure, pharma takes the top spot at 26.8%, followed by healthcare equipment (24.3%) and biotech (17.6%). The product has amassed nearly $2.6 billion in its asset base and charges 43 bps in annual fees. It trades in a good volume of around 35,000 shares a day and has a Zacks ETF Rank #2 with a Medium risk outlook.
This ETF tracks the MSCI US Investable Market Health Care 25/50 Index and holds 452 stocks in its basket. Of these, Johnson & Johnson occupies the top position with a 7.8% allocation. Pharma takes the largest share at 25%, while healthcare equipment and biotech round off the top three spots. VHT is also one of the popular and liquid ETFs with AUM of $14 billion and an average daily volume of about 245,000 shares. It charges 10 bps in annual fees and has a Zacks ETF Rank #2 with a Medium risk outlook.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
JNJ Touches New Highs Post Solid Q4 Earnings: ETFs in Focus
Johnson & Johnson (JNJ - Free Report) set the ball rolling for pharma and medical device manufacturer fourth-quarter 2021 earnings on Jan 26, before the opening bell. The world's biggest healthcare products maker continued its long streak of earnings beat and outpaced revenue estimates. Further, the company offered upbeat full-year outlook.
Earnings per share came in at $1.86, beating the Zacks Consensus Estimate of $1.81 and declining 1.1% from the year-ago quarter. Revenues grew 8.3% year over year to $22.5 billion and edged past the Zacks Consensus Estimate of $21.6 billion. The stronger performance was driven by strong sales for blockbuster immunology and cancer drugs, as well as consumer-health products such as Tylenol and Listerine.
For 2021, Johnson & Johnson expects revenues in the range of $90.5-$91.7 billion, indicating year-over-year increase of 9.5%-11%, and earnings per share guidance of $9.40-$9.60, up 17.1-19.6% year over year. The Zacks Consensus Estimate is pegged at $88.7 billion for revenues and $8.89 for earnings per share.
Additionally, the company expects the phase 3 COVID-19 vaccine data, which will be released early next week, to be robust, matching expectations that it will rival the efficacy offered by the Moderna (MRNA - Free Report) and Pfizer (PFE - Free Report) vaccines. JNJ vaccine is a big deal as it requires just one dose and can be stored at room temperature unlike its rivals (read: Can Moderna ETFs Gain on COVID Vaccine Update Against Variants?).
The solid results coupled with upbeat vaccine data optimism pushed JNJ shares to all-time high. Currently, the stock has a Zacks Rank #3 (Hold) and VGM Score of B.
ETFs in Focus
Given this, investors should closely watch the movement of the stock and ETFs having a largest allocation to this diversified drug maker. Below we have highlighted them (see: all the Healthcare ETFs here).
iShares U.S. Pharmaceuticals ETF (IHE - Free Report)
This ETF provides exposure to 43 companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. Of these, Johnson and Johnson takes the top spot, accounting for 23% share. The product has $366.8 million in AUM and charges 42 bps in fees and expenses. Volume is lower as it exchanges about 14,000 shares a day. The fund has a Zacks ETF Rank #3 (Hold) with a High risk outlook.
Health Care Select Sector SPDR Fund (XLV - Free Report)
The most-popular healthcare ETF, XLV follows the Health Care Select Sector Index. This fund manages nearly $26.4 billion in its asset base and trades in heavy volume of around 7.6 million shares. Expense ratio comes in at 0.13%. In total, the fund holds 63 securities in its basket, with JNJ taking the top spot, accounting for 10.1% of the assets. Pharma accounts for 29.3% share from a sector look, while healthcare equipment and supplies, healthcare providers and services, and biotech have a double-digit exposure each. It has a Zacks ETF Rank #2 (Buy) with a Medium risk outlook (read: 4 Sector ETFs & Stocks to Bet on Q4 Earnings).
iShares Evolved U.S. Innovative Healthcare ETF
This actively managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector. Holding 252 stocks in its basket, JNJ is the top firm with a 9.5% allocation. The product has accumulated $34.1 million in its asset base and trades in a meager volume of 12,000 shares per day on average. It charges 18 bps in annual fees.
iShares U.S. Healthcare ETF (IYH - Free Report)
This fund offers exposure to 123 securities by tracking the Dow Jones U.S. Health Care Index. Here again, Johnson & Johnson dominates the fund’s returns with 8.8% of the total assets. In terms of industrial exposure, pharma takes the top spot at 26.8%, followed by healthcare equipment (24.3%) and biotech (17.6%). The product has amassed nearly $2.6 billion in its asset base and charges 43 bps in annual fees. It trades in a good volume of around 35,000 shares a day and has a Zacks ETF Rank #2 with a Medium risk outlook.
Vanguard Health Care ETF (VHT - Free Report)
This ETF tracks the MSCI US Investable Market Health Care 25/50 Index and holds 452 stocks in its basket. Of these, Johnson & Johnson occupies the top position with a 7.8% allocation. Pharma takes the largest share at 25%, while healthcare equipment and biotech round off the top three spots. VHT is also one of the popular and liquid ETFs with AUM of $14 billion and an average daily volume of about 245,000 shares. It charges 10 bps in annual fees and has a Zacks ETF Rank #2 with a Medium risk outlook.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>